Form 8-K - Current report:
SEC Accession No. 0000950170-23-016869
Filing Date
2023-05-03
Accepted
2023-05-03 06:39:00
Documents
15
Period of Report
2023-04-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cere-20230427.htm   iXBRL 8-K 69111
2 EX-99.1 cere-ex99_1.htm EX-99 275674
3 GRAPHIC img106327088_0.jpg GRAPHIC 3034
4 GRAPHIC img106327088_1.jpg GRAPHIC 3034
  Complete submission text file 0000950170-23-016869.txt   493760

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cere-20230427_pre.xml EX-101.PRE 9841
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cere-20230427_lab.xml EX-101.LAB 13360
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cere-20230427.xsd EX-101.SCH 2466
9 EXTRACTED XBRL INSTANCE DOCUMENT cere-20230427_htm.xml XML 4720
Mailing Address 222 JACOBS STREET SUITE 200 CAMBRIDGE MA 02141
Business Address 222 JACOBS STREET SUITE 200 CAMBRIDGE MA 02141 844-304-2048
Cerevel Therapeutics Holdings, Inc. (Filer) CIK: 0001805387 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39311 | Film No.: 23881577
SIC: 2834 Pharmaceutical Preparations